Successful Treatment with Rituximab and Immunoadsorption for an Auto-Antibody Induced Bile Salt Export Pump Deficiency in a Liver Transplanted Patient.
Jesus Quintero BernabeuJavier JuamperezEmmanuel M GonzalesEcaterina JulioMaria Mercadal-HallyMauricette Collado-HillyAna MarínRamon CharcoPublished in: Pediatric gastroenterology, hepatology & nutrition (2020)
We present an 8 years old girl who was diagnosed at 6 months of age of Progressive Familial Intrahepatic Cholestasis type 2. Although liver transplantation (LT) was classically considered curative for these patients, cholestasis recurrence with normal gamma-glutamyl transpeptidase (GGT), mediated by anti-bile salt export pump (BSEP) antibodies after LT (auto-antibody Induced BSEP Deficiency, AIBD) has been recently reported. Our patient underwent LT at 14 months. During her evolution, patient presented three episodes of acute rejection. Seven years after the LT, the patient presented pruritus with cholestasis and elevation of liver enzymes with persistent normal GGT. Liver biopsy showed intrahepatic cholestasis and giant-cell transformation with very low BSEP activity. Auto-antibodies against BSEP were detected therefore an AIBD was diagnosed. She was treated with Rituximab and immunoadsorption with resolution of the AIBD. As a complication of the treatment she developed a pneumocystis infection successfully treated with corticoids, cotrimoxazol and anidulafungin.
Keyphrases
- drug induced
- case report
- end stage renal disease
- newly diagnosed
- high glucose
- multiple sclerosis
- chronic kidney disease
- diffuse large b cell lymphoma
- diabetic rats
- endothelial cells
- early onset
- replacement therapy
- liver failure
- peritoneal dialysis
- hodgkin lymphoma
- acute respiratory distress syndrome
- ultrasound guided
- single molecule
- mechanical ventilation
- chronic lymphocytic leukemia